C4 THERAPEUTICS INC. - COMMON STOCK
4.2500
22-نوفمبر-24 16:44:58
15 متأخرة بدقائق
الأسهم
+0.2400
+5.99%
نطاق اليوم
3.9100 - 4.3385
ISIN
N/A
المصدر
NASDAQ
-
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
04 مايو 2023 07:00:01 بحسب Nasdaq GlobeNewswire
-
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
19 أبريل 2023 07:00:00 بحسب Nasdaq GlobeNewswire
-
23 فبراير 2023 07:00:02 بحسب Nasdaq GlobeNewswire
-
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
08 فبراير 2023 07:00:00 بحسب Nasdaq GlobeNewswire
-
30 يناير 2023 07:00:00 بحسب Nasdaq GlobeNewswire
-
09 يناير 2023 07:00:01 بحسب Nasdaq GlobeNewswire
-
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 يناير 2023 07:00:01 بحسب Nasdaq GlobeNewswire
-
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
03 نوفمبر 2022 07:00:02 بحسب Nasdaq GlobeNewswire
-
29 سبتمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire
-
C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022
26 سبتمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire
-
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
04 أغسطس 2022 08:00:03 بحسب Nasdaq GlobeNewswire
-
02 أغسطس 2022 08:00:03 بحسب Nasdaq GlobeNewswire
-
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
05 مايو 2022 08:00:02 بحسب Nasdaq GlobeNewswire
-
08 أبريل 2022 13:00:00 بحسب Nasdaq GlobeNewswire
-
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
16 مارس 2022 16:05:00 بحسب Nasdaq GlobeNewswire
-
09 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire
-
08 مارس 2022 16:30:00 بحسب Nasdaq GlobeNewswire
-
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
24 فبراير 2022 07:00:03 بحسب Nasdaq GlobeNewswire
-
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
10 يناير 2022 07:00:02 بحسب Nasdaq GlobeNewswire